Table 3.
Differentiation between O25-ST131 and Non-O25-ST131 E. coli Isolates
| n= (Urinary+Intestinal) | O25-ST131 | Non O25-ST131 | P-value | |||
|---|---|---|---|---|---|---|
| Urinary Isolates | Intestinal Isolates | Urinary Isolates | Intestinal Isolates | |||
| Phylogenetic group | B2, n=(32+5) | 30/32 (93.8%) | 5/5 (100%) | 2/32 (6.2%) | 0/5 0 | 1.000 |
| B1, n=(30+39) | 23/30 (76.7%) | 12/39 (30.8%) | 7/30 (23.3%) | 27/39 (69.2%) | <0.001* | |
| A, n=(26+44) | 24/26 (92.3%) | 25/44 (56.8%) | 2/26 (7.7%) | 19/44 (43.2%) | 0.002* | |
| D, n=(17+12) | 12/17 (70.6%) | 5/12 (41.7%) | 5/17 (29.4%) | 7/12 (58.3%) | 0.148 | |
| MDR n= (65+56) | 58 (89.2%) | 42 (75%) | 7 (10.8%) | 14 (25%) | 0.039* | |
| ESBLs positive (synergy test) n=(79+71) | 66 (83.5%) | 41 (57.7%) | 13 (16.5%) | 30 (42.3%) | <0.001* | |
| CTX-M-15, n=(57+66) | 45 (78.9%) | 35 (53%) | 12 (21.1%) | 31 (47%) | 0.004* | |
| Antibiotic resistance | AMC (88+80) | 74 (84.1%) | 45 (56.2%) | 14 (15.9%) | 35 (43.8%) | <0.001* |
| CAZ (62+53) | 53 (85.5%) | 38 (71.7%) | 9 (14.5%) | 15 (28.3%) | 0.07 | |
| CRO (78+71) | 66 (84.6%) | 42 (59.2%) | 12 (15.4%) | 29 (40.8%) | 0.001* | |
| STX (66+54) | 59 (89.4%) | 41 (75.9%) | 7 (10.6%) | 13 (24.1%) | 0.049* | |
| AMK (25+21) | 24 (96%) | 14 (66.7%) | 14 (4%) | 7 (33.3%) | 0.016* | |
| CIP (31+35) | 25 (80.6%) | 29 (82.9%) | 6 (19.4%) | 6 (17.1%) | 0.816 | |
| IPM (2+4) | 2 (100%) | 4 (100%) | 0 | 0 | ||
Note: *P-value is significant.
Abbreviations: MDR, Multi-Drug Resistant; ESBLs, Extended Spectrum B-Lactamases; AMC, Amoxicillin-clavulanate; CAZ, Ceftazidime; CRO, Ceftriaxone; SXT, sulfamethoxazole -Trimethoprim; AMK, Amikacin; IPM, Imipenem; CIP, Ciprofloxacin; n, number.